These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 30302987)

  • 1. Proteinuria in children with autosomal dominant polycystic kidney disease.
    Seeman T; Pohl M; John U
    Minerva Pediatr; 2018 Oct; 70(5):413-417. PubMed ID: 30302987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profiling proteinuria in children after renal transplantation.
    Seeman T; Dusek J; Vondrák K; Spatenka J; Feber J
    Pediatr Nephrol; 2009 Dec; 24(12):2439-44. PubMed ID: 19657680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors relating to urinary protein excretion in children with autosomal dominant polycystic kidney disease.
    Sharp C; Johnson A; Gabow P
    J Am Soc Nephrol; 1998 Oct; 9(10):1908-14. PubMed ID: 9773792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4.
    Ruggenenti P; Gentile G; Perico N; Perna A; Barcella L; Trillini M; Cortinovis M; Ferrer Siles CP; Reyes Loaeza JA; Aparicio MC; Fasolini G; Gaspari F; Martinetti D; Carrara F; Rubis N; Prandini S; Caroli A; Sharma K; Antiga L; Remuzzi A; Remuzzi G;
    Clin J Am Soc Nephrol; 2016 May; 11(5):785-794. PubMed ID: 26912555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypomagnesaemia is absent in children with autosomal dominant polycystic kidney disease.
    Seeman T; Fořtová M; Sopko B; Průša R; Pohl M; John U
    Ann Clin Biochem; 2019 Jan; 56(1):90-94. PubMed ID: 29874928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of urinary endothelin-1 with estimated glomerular filtration rate in autosomal dominant polycystic kidney disease: a pilot cross-sectional analysis.
    Raina R; Lou L; Berger B; Vogt B; Do AS; Cunningham R; Vasavada P; Herrmann K; Dell K; Simonson M
    BMC Nephrol; 2016 Feb; 17():22. PubMed ID: 26923419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis.
    Meijer E; Boertien WE; Nauta FL; Bakker SJ; van Oeveren W; Rook M; van der Jagt EJ; van Goor H; Peters DJ; Navis G; de Jong PE; Gansevoort RT
    Am J Kidney Dis; 2010 Nov; 56(5):883-95. PubMed ID: 20888104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.
    Gansevoort RT; Meijer E; Chapman AB; Czerwiec FS; Devuyst O; Grantham JJ; Higashihara E; Krasa HB; Ouyang J; Perrone RD; Torres VE;
    Nephrol Dial Transplant; 2016 Nov; 31(11):1887-1894. PubMed ID: 26681730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations.
    Spithoven EM; Meijer E; Boertien WE; Sinkeler SJ; Tent H; de Jong PE; Navis G; Gansevoort RT
    Am J Kidney Dis; 2013 Sep; 62(3):531-40. PubMed ID: 23714171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertension in autosomal dominant polycystic kidney disease: a meta-analysis.
    Marlais M; Cuthell O; Langan D; Dudley J; Sinha MD; Winyard PJ
    Arch Dis Child; 2016 Dec; 101(12):1142-1147. PubMed ID: 27288429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early renal abnormalities in children with postnatally diagnosed autosomal dominant polycystic kidney disease.
    Selistre L; de Souza V; Ranchin B; Hadj-Aissa A; Cochat P; Dubourg L
    Pediatr Nephrol; 2012 Sep; 27(9):1589-93. PubMed ID: 22689086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early cardiovascular manifestations in children and adolescents with autosomal dominant polycystic kidney disease: a single center study.
    Karava V; Benzouid C; Hogan J; Dossier C; Denjean AP; Deschênes G
    Pediatr Nephrol; 2018 Sep; 33(9):1513-1521. PubMed ID: 29774463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic heterogeneity in pediatric autosomal dominant polycystic kidney disease at first presentation: a single-center, 20-year review.
    Tee JB; Acott PD; McLellan DH; Crocker JF
    Am J Kidney Dis; 2004 Feb; 43(2):296-303. PubMed ID: 14750095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Blood pressure, functional and morphological study of kidneys in children with autosomal dominant polycystic kidney disease].
    Seeman T; Vondrichová H; Strízová J; Sikut M; Janda J; Schärer K
    Cas Lek Cesk; 1999 Mar; 138(6):178-84. PubMed ID: 10510532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cystatin C estimated glomerular filtration rate to assess renal function in early stages of autosomal dominant polycystic kidney disease.
    Sans L; Radosevic A; Quintian C; Montañés R; Gràcia S; Vilaplana C; Mojal S; Ballarin JA; Fernández-Llama P; Torra R; Pascual J
    PLoS One; 2017; 12(3):e0174583. PubMed ID: 28346513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease.
    Helal I; Reed B; McFann K; Yan XD; Fick-Brosnahan GM; Cadnapaphornchai M; Schrier RW
    Clin J Am Soc Nephrol; 2011 Oct; 6(10):2439-43. PubMed ID: 21903987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between renal volume and renal function in autosomal dominant polycystic kidney disease.
    Tokiwa S; Muto S; China T; Horie S
    Clin Exp Nephrol; 2011 Aug; 15(4):539-45. PubMed ID: 21431900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with autosomal dominant polycystic kidney disease hyperfiltrate early in their disease.
    Wong H; Vivian L; Weiler G; Filler G
    Am J Kidney Dis; 2004 Apr; 43(4):624-8. PubMed ID: 15042539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Podocyte Injury in Autosomal Dominant Polycystic Kidney Disease.
    Cebeci E; Ekinci I; Gursu M; Coskun C; Karadag S; Uzun S; Behlul A; Senel TE; Kazancioglu R; Ozturk S
    Nephron; 2019; 142(4):311-319. PubMed ID: 31117091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.